News

Article

New Generation of CAR T May Elicit Improved CR Rates in CLL

Key Takeaways

  • Third-generation CAR T-cell therapy shows promising efficacy and safety in heavily pretreated CLL patients, with a 67% complete response rate.
  • The new CAR T-cell generation aims to mitigate exhaustion seen in second-generation therapies by incorporating costimulatory domains.
SHOW MORE

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

A new generation of chimeric antigen receptor T-cell therapy has shown promising efficacy and safety in a small study of heavily pretreated patients with chronic lymphocytic leukemia (CLL).

Results of the early-/mid-stage study, published in Leukemia, found encouraging response rates and other indicators of efficacy, as well as favorable safety, with third-generation CAR T cells among patients with relapsed or refractory disease. If confirmed in late-stage trials, the approach could serve as a new option for relapsed/refractory patients.

CAR T-cell therapy | Image credit: AIGen - stock.adobe.com

The goal of third-generation CAR T-cell therapies is to mitigate the exhaustion observed with second-generation options, potentially by modifying the CAR vector. | Image credit: AIGen - stock.adobe.com

“Over the past two decades, the landscape of CLL therapy has undergone a significant transformation, moving away from chemoimmunotherapy approaches towards the adoption of targeted therapies, notably BTK and B-cell lymphoma 2 inhibitors,” wrote the researchers of the study. "However, challenges persist as in particular patients with genetically high-risk CLL tend to develop resistance to these targeted therapies with a consecutive dismal outlook.”

Second-generation CAR T-cell therapies, such as lisocabtagene maraleucel (liso-cel; Breyanzi),2 have changed the course of treatment for certain types of B-cell malignancies, including CLL. However, responses to these cell-based treatments in CLL have lagged behind those seen in other indolent B-cell lymphomas, including in non-Hodgkin lymphoma.3

The goal of third-generation CAR T-cell therapies is to mitigate the exhaustion observed with second-generation options, potentially by modifying the CAR vector. The new generation of CARs have 2 costimulatory domains to alleviate exhaustion and allow for enhanced and quicker expansion.

With limited data on the potential of third-generation CARs, researchers treated 9 patients, who had previously received a median 5 prior treatments, with HD-CAR-1. Patients included in the trial were a median age of 60 years and had all previously received treatment with a Bruton tyrosine kinase inhibitor and a venetoclax-based regimen.

Three months after receiving treatment, 6 (67%) patients had achieved a complete response (CR), with 5 (83%) showing undetectable minimal residual disease. With a median follow-up of 27 months, 69% of patients were still alive and the progression-free survival (PFS) rate was 30%. Achieving a CR was associated with better PFS, with patients who achieved a CR having significantly longer PFS than those who did not (median PFS 12.1 months vs 3.8 months; P = .024).

These findings suggest that third-generation CAR T-cell therapy may elicit improved CRs in patients refractory to other treatments, explained the researchers, noting that CR rates of current CAR T-cell approaches have been suboptimal.

Data from 117 patients in the pivotal liso-cel trial—TRANSCEND CLL 004 (NCT03331198)—showed an overall response rate of 48% and CR rate of 18%, with most CR rates showing durability.

“The low CR rate observed in these trials prompted us to attempt debulking of leukemia cell load prior to HD-CAR-1 treatment to facilitate CAR T efficacy and at the same time to reduce toxicity risks,” explained the researchers. “In most heavily pretreated patients this was successfully achieved by using venetoclax-CD20 antibody combinations despite prior failure of fixed-duration venetoclax.” 

Safety data from TRANSCEND CLL 004 showed grade 3 cytokine release syndrome(CRS) reported in 10 (9%) of patients treated with liso-cel and grade 3 neurological events reported in 21 (18%). There were no grade 4 or 5 CRS events and 1 grade 4 neurological event.4

Findings from this current study showed 1 case of grade 3 CRS, though CRS overall occurred in 7 patients, and no cases of neurotoxicity.1 Immune effector cell–associated hematotoxicity (ICAHT) was observed early on in 8 (89%) patients, with 1 patient experiencing grade 4 ICAHT. Late ICAHT occurred in 3 patients (one grade 1 and two grade 2), none of which required granulocyte colony-stimulating factor therapy.

References

  1. Derigs P, Schubert M-L, Dreger P, et al. Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 2024:38-2419-2428. doi:10.1038/s41375-024-02392-7
  2. Bristol Myers Squibb. U.S. FDA approved Bristol Myers Squibb’s Breyanzi® as the first and only CAR T cell therrapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). March 14,2024. Accessed November 26, 2024. https://news.bms.com/news/details/2024/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi--as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL/default.aspx
  3. Neelapu SS, Chavex JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtageneciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496-506. doi:10.1182/blood.2023021243
  4. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagenemaraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;401(10402):641-654. doi:10.1016/S0140-6736(23)01052-8
Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
4 experts are featured in this series.
1 expert is featured in this series.
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
John Ostrominski, MD
John Buse, MD, PhD
Christian T. Ruff, MD, MPH
Dr Geoffrey Rutledge
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo